Neurobiology of Disease

Monomeric IgG Is Neuroprotective via Enhancing Microglial Recycling Endocytosis and TNF-α

Department of Neurology, The University of Chicago Medical Center, Chicago, Illinois 60637

In brain, monomeric immunoglobulin G (IgG) is regarded as quiescent and only poised to initiate potentially injurious inflammatory reactions via immune complex formation associated with phagocytosis and tumor necrosis factor α (TNF-α) production in response to disease. Using rat hippocampal slice and microglial cultures, here we show instead that physiological levels (i.e., 0.2–20 μg/ml) of monomeric IgG unassociated with disease triggered benign low-level proinflammatory signaling that was neuroprotective against CA1 area excitotoxicity and followed a U-shaped or hormetic dose–response. The data indicate that physiological IgG levels activated microglia by enhancing recycling endocytosis plus TNF-α release from these cells to produce the neuroprotection. Minocycline, known for its anti-inflammatory and neuroprotective effects when given after disease onset, abrogated IgG-mediated neuroprotection and related microglial effects when given before injury. In contrast, E-prostanoid receptor subtype 2 (EP2) activation, which served as an exemplary paracrine stimulus like the one expected from neuronal activity, amplified IgG-mediated increased microglial recycling endocytosis and TNF-α production. Furthermore, like monomeric IgG these EP2 related effects took days to be effective, suggesting both were adaptive anabolic effects consistent with those seen from other long-term preconditioning stimuli requiring de novo protein synthesis. The data provide the first evidence that brain monomeric IgG at physiological levels can have signaling function via enhanced recycling endocytosis/TNF-α production from microglia unassociated with disease and that these IgG-mediated changes may be a means by which paracrine signaling from neuronal activity influences microglia to evoke neuroprotection. The data provide further support that low-level proinflammatory neural immune signaling unassociated with disease enhances brain function.

Key words: cytokine; slice cultures; neuroprotection; neuroinflammation; hippocampus; endocytosis; hormesis

Introduction

Immunoglobulin G (IgG) is well recognized not only for its involvement in inflammatory reactions to neurological disease but also as an anti-inflammatory therapy to reduce brain disease (Fergusson et al., 2005; Arumugam et al., 2007). Monomeric IgG is a normal constituent of mammalian CSF (i.e., at ~133 nM or 20 μg/ml) and so can be expected to be similarly present within brain interstitial space (Cséř, 1974). Its level there is orders of magnitude less than that of blood, where IgG emanates from B-cells (Lanzavecchia, 1983). The low level of IgG in brain suggests that IgG is restricted there, perhaps via high affinity neonatal Fc receptors localized to brain endothelial cells known to saturate at 10–1000 nM (Zhang and Pardridge, 2001), a range that includes physiological concentrations in brain. Conceivably, monomeric IgG exists in brain only as a quiescent signaling molecule prepared to initiate immune reactions via formation of immune complexes (Gessner et al., 1998; Nimmerjahn and Ravetch, 2006) in response to disease because it has no defined function in non-diseased brain.

However, monomeric IgG at levels physiological to the brain reacts specifically with its high affinity cognate receptor, FcγRI, which is found on microglia, so-called immune cells of brain (Kennedy et al., 1980). Like their macrophage counterparts in the periphery, which completely recycle their surface membrane in little over 1 h (Mukherjee et al., 1997), microglia show a high degree of endocytosis. Evidence shows that monomeric IgG can signal via recycling endocytosis involving FcγRI (Mellman et al., 1984; Harrison et al., 1994; Barnes et al., 2002). Furthermore, recycling endocytosis is used to shuttle proteins to the external milieu (Ang et al., 2004; Murray et al., 2005), and macrophages use this piggy-back transport format to release tumor necrosis factor α (TNF-α) associated with phagocytosis (Murray et al., 2005), and so generate cytotoxic levels of this innate cytokine that can enhance disease severity (Barone et al., 1997; Zou and Crew, 2005).

In contrast, physiological TNF-α levels enhance synaptic transmission (Beattie et al., 2002) and enhanced synaptic transmission associated with learning is neuroprotective (Will et al., 2004). Accordingly, we used rat hippocampal slice cultures and...
primary microglia cultures to show that chronic (but not acute) treatment with monomeric IgG at physiological levels triggered neuroprotection against excitotoxic injury to CA1 pyramidal neurons via activation of microglia that includes enhanced recycling endocytosis and TNF-α release. Furthermore, abrogation of microglial activation using minocycline prevented IgG-based neuroprotection and microglial recycling endocytosis/TNF-α change. We also used E-prostanoid receptor subtype 2 (EP2) activation, as an exemplary paracrine signal from neural activity, to suggest that prostaglandin E2 (PGE2), released with increased pyramidal neuron activity, could amplify these newly defined monomeric IgG effects on microglial recycling endocytosis and TNF-α. Together, the results show that microglial recycling endocytosis-associated TNF-α production and neuronal vitality (and perhaps activity) may be reciprocally connected via monomeric IgG trafficking. This work has appeared in preliminary form (Hulse et al., 2006; Kraig et al., 2007).

Materials and Methods

Determination of rat CSF IgG level. Adult rats (n = 5; 300–320 gm) were anesthetized with intraperitoneal pentobarbital (50 mg/kg) and placed in a standard stereotaxic unit. CSF (anesthetized with intraperitoneal pentobarbital (50 mg/kg) and placed in a standard stereotaxic unit. CSF (−60–100 μl/animal) was withdrawn at the atlanto-occipital junction via a 26 gauge needle and tuberculin syringe mounted on a Narishige micromanipulator from a sterile exposure of the dorsal neck at the occiput-upper cervical spine. Samples were stored at −80°C until quantification for IgG via microsphere-immunoassay. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Chicago.

Culture preparation and maintenance. Slice cultures are widely accepted experimental models and were prepared as previously described (Kunkler and Kraig, 1997; Kunkler et al., 2004, 2005). However, after 4 d in vitro, they were transferred to a serum-free media to reduce potentially confounding effects of serum and allow study of IgG effects (see Results and supplemental materials, available at www.jneurosci.org). The serum-free media consisted of 96% Neurobasal (Invitrogen) supplemented to a total glucose concentration of 42 mm, 1 mm glutamine (Sigma), 2% B27 supplement, 10 μg/ml gentamicin and 250 μg/ml Fungizone (Invitrogen). Slice cultures were incubated at 36°C with 5% CO2 balance air and media was changed twice a week. Slices were maintained 21–30 d in vitro before use.

Primary microglia cultures were prepared as previously described (Caggiano and Kraig, 1999) using Dulbecco’s Modified Medium (D5976; Sigma) plus 10% fetal bovine serum (#10082–147; Invitrogen) and 10 μg/ml gentamicin (Invitrogen) (DMEM–10).

Experimental manipulations. We examined whether IgG could be neuroprotective by exposing slice cultures to nonspecific pooled rat IgG (#012–000-003) or nonspecific pooled F(ab')2 fragment (#115–006-003) in serum-free media (Jackson Immunoresearch) for 3 d. IgG doses were 0.2, 2.0, 20, 200 or 2000 μg/ml given for 3 d before and during injury (i.e., chronic exposure). The impact of acute exposure (i.e., 6 h before injury and immediately after injury) to IgG was also examined as well as prolonged exposure for 17 d. Exposure to F(ab')2 (3 d) was performed at IgG doses (0.2, 2.0, 20 μg/ml) protective against excitotoxic injury. Serum-free media containing treatments were refreshed on the third day before injury inductions.

To discover whether immune complexes could influence potential effects from IgG, we exposed slice cultures for 3 d to immune complexes formed from equal volumes of chicken-ovalbumin (2 μg/ml; #A2512; Sigma) and affinity purified rabbit anti-ovalbumin IgG (40 μg/ml; #ROL-30A; Immunology Consultants Laboratory) mixed and incubated at 36°C for 30 min before use. Sodium azide was removed from rabbit anti-ovalbumin IgG via dialysis.

We tested whether IgG effects were related to TNF-α by use of soluble TNF receptor 1 (sTNFR1, 200 ng/ml; #425-R1–050; R & D Systems) to abrogate TNF-α signaling. Recombinant rat TNF-α (#510-RT; R & D Systems) was applied to slice cultures (100 pg/ml) to mimic TNF-α secretion from IgG exposure. Minocycline (10 μM, #M9511; Sigma) was used to inhibit microglial activation (Lai and Todd, 2006).

Sham experiments consisted of heat-inactivated IgG, F(ab')2 fragments or recombinant (i.e., sTNFR1 and TNF-α) proteins [made by exposure to 95°C (10 min) followed by ice (10 min) before use]. This was done to denature experimental proteins, and so remove their potential effects. However, production of recombinant proteins (i.e., TNF-α and sTNFR1 in experiments here) involved use of E. coli, which might contain endotoxin contamination (Gao and Tsan, 2003). The latter itself can have cellular and tissue affects (de Bock et al., 1998; Rosenzweig et al., 2004; Weissman and Welsh, 2004). This effect was not seen.

As noted above, we included specific treatments for 3 d before injury and during exposure to N-methyl-D-aspartate (NMDA; #454575; Cal Biochem) or oxygen-glucose deprivation (OGD) but not during subsequent maximal injury (see below). However, with this paradigm O2-mediated neuroprotection was so robust that it also markedly reduced maximal injury compared with other groups and so gave falsely elevated injury ratios. Accordingly, for experiments involving EP2-activation (see Fig. 8), treatments were continued for only 3 d and then excluded from injury and maximal injury exposures. Results for IgG between this and the former paradigm were comparable (see Figs. 1, 8). No treatments were included in either paradigm during maximal injury exposure.

Excitotoxic injury and quantification. Excitotoxic injury and quantification of slice culture CA1 area followed that reported by McCullough et al. (2004) with modifications described below. We used NMDA to trigger excitotoxic injury of CA1 area pyramidal neurons. Before NMDA exposure, slice cultures were screened for evidence of pyramidal cell neuronal death by incubating cultures for 20 min in serum-free media containing Sytox Green (500 μM, #S7020; Invitrogen). If CA1 pyramidal layer injury was seen (i.e., >20 Sytox positive cells), involved slice cultures were excluded; otherwise initial culture images were acquired (for background subtraction) using a Cool Snap fx CCD camera (Photometrics) and MetaMorph (v 7.0.4) software (Molecular Devices) on an inverted Leica DM-IRBE microscope (Leica Mikroskopie und Systeme). Slice cultures were then exposed to NMDA (20 μM) in serum-free media for 60 min under normal incubation conditions (as defined above). After exposure the underside of each insert was rinsed by dipping it gently once each in three 60 mm dishes filled with 10 ml of Neurobasal (36°C) and then returned to the incubator in fresh serum-free media. Twenty-four hours later, injury was quantified by re-incubating slice cultures for 20 min in media containing Sytox Green and then acquiring images of injury. Finally, neuronal death in CA1 was maximized by overnight exposure to serum-free media containing 20 μM NMDA. Final images were acquired after 20 min incubations in Sytox Green.

To further establish the applicability of slice culture excitotoxicity effects in the in vivo condition we also used OGD to trigger CA1 area excitotoxic injury via methods that were modified from Newell et al. (1995). All cultures were prescreened to determine existing CA1 injury (i.e., >20 Sytox-positive cells in CA1 excluded) before exposure. The OGD chamber consisted of an airtight Plexiglas chamber (47 × 27 × 22 cm) with controlled humidity (#8534–025), temperature (#8535–025), and CO2 (#8528110; Goy Laboratory Products).

O2 levels were monitored with a USB-LS-450 Foxys O2 sensing probe (Ocean Optics). Two point calibrations [0% and room air (i.e., 21% O2)] were performed at 36°C and 85% humidity for the O2 probe following the manufacturer’s procedure before OGD. OGD consisted of placing slice culture inserts in a modified ischemic Ringer’s solution (in mM): 33 sodium lactate, 75 KCl, 17.9 NaHCO3, 0.1 CaCl2, 1.6 MgCl2 (Bondarenko and Chersler, 2001). The sealed chamber was flushed with N2 (<1 min) until O2 levels fell <1% which was then changed to 85% N2, 15% CO2 at 36°C and 85% humidity. A CO2 percentage of 15% was chosen to acidify the ischemic Ringer’s to pH 6.8 (Bondarenko and Chersler, 2001). Slice cultures were exposed for 1 h to OGD, rinsed three times with 10 ml of Neurobasal (36°C), returned to normoxic conditions in appropriate media (i.e., control or treated), and further processed as described for NMDA injury.

Calibration of the imaging system for NMDA and OGD consisted of setting the CCD camera to a uniform full image intensity (1000/4096) of the fluorescence in response to a fluorescein standard (#F36915; Invitro-
L-lysine, and 37 mM phosphate buffer, 6.2 pH) or 4% paraformaldehyde-merced in methanol at workers (Lewis et al., 1985). After fixation, primary microglia were im-

Prolong Antifade (#P7481; Invitrogen).

Before acquisitions, the imaging system was calibrated to register uniform full image intensity (2000/4096) to a fluorescein standard (488 nm excitation). Images were acquired at either 488 nm excitation (endocy-

osis) or 594 nm excitation (RAB11a and LAMPI). We used a confocal microscope (Leica SP2 A1BS) to create representative images of IgG-

induced changes in primary microglial endocytosis and RAB11a plus LAMP1 staining (see below). Images were flattened from z-stacks made from 30 to 60 image planes taken every 1–2 μm.

Fast performance liquid chromatography. Fast performance liquid chromatography was used to confirm the absence of immune complexes (i.e., protein components above a monomeric IgG molecular weight of ~150 kDa) (Dorrington and Tanford, 1970) derived from IgG in media containing IgG, immune complexes, or related heat-inactivated shams.

IgG and/or IgG–IgG complexes could be isolated. In addition, potentially confounding eff-

serum-free media, where the content and therefore the effect of

IgG could have signaling function in noninjured brain. We have

previously grown slice cultures in media containing 23% horse

IgG can have signaling function in noninjured brain. We have

we sought to explore whether physiological levels of monomeric

IgG can have signaling function in noninjured brain. We have

IgG can have signaling function in noninjured brain. We have

IgG can have signaling function in noninjured brain. We have

...
horse, and swine) CSF IgG is normally 10–13 μg/ml (Spector, 1956; Wurster and Haas, 1994) and CSF constituents fairly estimate comparable constituent levels in brain interstitial space (Csern, 1974). However, rat CSF IgG levels have not been reported, prompting us to determine that adult rat (296–308 gm; n = 5) CSF contains 16 ± 2 μg/ml (or 107 nm). Furthermore, albumin is often included with use of such low-level proteins to maintain bioactivity by preventing adsorption to plastic ware. However, albumin is already in excess seen in normal CSF (i.e., 500–1000:1 ratio) (Spector, 1956; Wurster and Haas, 1994).

Microglial cultures (i.e., > 99% microglia) deteriorate, and so initially become reactive, under serum-free conditions. Accordingly, microglial cultures were maintained in media with 10% fetal bovine serum (FBS) (e.g., could trigger spreading depression for the first time from a single electrical pulse, a level of excitability seen in vivo). The characterization is detailed in supplemental Methods (available at www.jneurosci.org as supplemented material).

**Characterization of slice cultures in serum-free media**

We characterized slice cultures grown in serum-free media to confirm that they were comparable with those previously grown in horse serum-based media. Briefly, slice cultures prepared and used in serum-free media were not only comparable with those from serum-based media, but they showed improved physiological function (e.g., could trigger spreading depression for the first time from a single electrical pulse, a level of excitability seen in vivo). The characterization is detailed in supplemental Methods (available at www.jneurosci.org as supplemented material).

**IgG-induced neuroprotection in slice cultures**

We used NMDA mediated excitotoxicity to model neurodegenerative diseases, including ischemia, that mainly affect CA1 pyramidal neurons, whereas OGD was used as a confirmatory in vitro model for injury from ischemia (Newell et al., 1995). Pooled, nonspecific IgG triggered U-shaped neuroprotective responses (Fig. 1). Over the dose range 0.2, 2.0, 20, 200, 2000 μg/ml IgG, pretreatment produced significant neuroprotection at 2.0 and 20 μg/ml but not at other doses against NMDA injury. Similarly, IgG pretreatment evoked significant neuroprotective effects against OGD at 0.2, 2.0 and 20 μg/ml but not at 200 and 2000 μg/ml.
We next showed that intact IgG was required for neuroprotection (Fig. 1). IgG heat inactivation at exemplary doses that otherwise would reduce NMDA-mediated injury now had no influence over injury severity. Similarly, heat inactivation of IgG doses that otherwise would be protective against OGD were not protective. Incubations with the F(ab′)2 portion of pooled IgG at the same doses \((n = 6/\text{group})\) also failed to elicit neuroprotection \((p < 0.001; \alpha = 1.00)\) enhanced U-shaped neuroprotective response and shifted its maximum to the left. In addition, high dose IgG \((20 \mu\text{g/ml})\) significantly \((p < 0.001; \alpha = 1.00)\) increased injury. Relative levels of injury over the dose range were \(0.39 \pm 0.07\) \((n = 9), 0.56 \pm 0.05\) \((n = 5), 0.74 \pm 0.02\) \((n = 7), 0.94 \pm 0.03\) \((n = 5)\) and \(1.38 \pm 0.12\) \((n = 5)\) versus control \([1.00 \pm 0.08\) \((n = 9)\). Furthermore, IgG treatment \((20 \mu\text{g/ml})\)
for 6 h did not trigger neuroprotection against NMDA exposure or OGD (p = 0.19; α = 0.14 and p = 0.25; 0.10, respectively) with relative injury levels of 0.93 ± 0.04 (n = 9) versus control [1.00 ± 0.03 (n = 6)] and 0.97 ± 0.02 (n = 9) versus control [1.00 ± 0.04 (n = 6)], respectively. TNF-α expression was significantly elevated (p < 0.001; α = 1.00) over control at 6 h of IgG treatment (20 μg/ml) with relative levels of 3.53 ± 0.05 (n = 13) and 1.00 ± 0.16 (n = 13), which is consistent with the rapid expression after stimulation of this cytokine (Lee et al., 1993; Mascher et al., 1999).

**Microglial activation with IgG-mediated neuroprotection**

IgG (i.e., Fc) receptors are expressed on microglia (in contrast to neurons, astrocytes or oligodendrocytes) in normal brain (Kennedy et al., 1980). Thus, we asked whether IgG-based neuroprotection involved microglial activation (Fig. 2). Three day exposures to IgG evoked a nonlinear, progressive increase in microglial cell body size (a change that denotes microglial activation to a “primed” state (Streit, 1995), shown via CD11b immunostaining). Specifically, IgG triggered a significant increase in cell size (compared with control slice cultures) at 20, 200, and 2000 μg/ml, whereas heat-inactivated IgG (2.0 μg/ml), 0.2 and 2.0 μg/ml IgG had no effect. Immunostaining for ED-1 (CD68), an endosomal/lysosomal marker (Bauer et al., 1994) that also reflects microglial activation (Streit, 1995), showed a similar nonlinear, progressive activation by IgG. Here, IgG triggered a significant increase in positive cell number at 20, 200, and 2000 μg/ml whereas 0.2, 2.0 μg/ml IgG and heat-inactivated IgG (2.0 μg/ml) had no effect. Thus, these markers of reactive microglial change did not parallel the U-shaped neuroprotective responses seen over the IgG dose range.

Monomeric IgG binds selectively to the high affinity Fc receptor, FcγR1, at neuroprotective IgG levels (Mellman et al., 1984; Harrison et al., 1994; Gessner et al., 1998; Barnes et al., 2002; Nimmerjahn et al., 2006); and might consequently influence microglial recycling endocytosis because ligand-receptor interactions are commonly followed by surface membrane trafficking that includes recycling endocytosis (Gaborik and Hunyady, 2004; Maxfield and McGraw, 2004). Use of microglia in primary culture confirmed this hypothesis (Fig. 3). As a screening test, we examined endocytotic uptake of 20 nm fluorescent beads. Twenty minutes is sufficient time for recycling endocytosis to reach a steady-state (Mukherjee et al., 1997), and this period of IgG exposure was sufficient to trigger a significant increase in uptake of beads at 0.2 μg/ml, no change at 2.0 μg/ml, and significant decreases in uptake at 20, 200, 2000 μg/ml. Although significantly increased uptake at 0.2 μg/ml IgG begins to be consistent with the U-shaped IgG-neuroprotective response, the basis for the progressive decrease in uptake from 2.0–2000 μg/ml is unclear. Nanometer beads may not selectively reflect recycling endocytosis for a host

**Figure 3.** Neuroprotective levels of IgG selectively increased primary microglial recycling endocytosis. **A–D.** Endocytosis of 20 nm fluorescent beads for 20 min is shown under control conditions (A) and after inclusion of IgG (2.0 μg/ml (B) or 2000 μg/ml (C)) and was quantified (D) as relative fluorescence density compared with control. Low (0.2 μg/ml) IgG triggered a significant (p < 0.001; α = 1.00) increase in endocytosis, whereas 2.0 μg/ml had no effect, and higher doses (20, 200, and 2000 μg/ml) triggered significant (p < 0.001; α = 1.00) decreases (with relative levels of 1.20 ± 0.04 (n = 131 cells), 1.10 ± 0.05 (n = 72), 0.68 ± 0.04 (n = 70), 0.72 ± 0.02 (n = 112) and 0.67 ± 0.02 (n = 114) versus control (1.00 ± 0.04; n = 107)). Immunostaining for specific endosomal subtypes (E–G and I–K, with related phase contrast images shown immediately below) parallel this U-shaped impact of monomeric IgG on endocytosis. E–H, RAB11a immunostaining, a marker for recycling endocytosis, showed a significant increase (p < 0.001; α = 1.00) from control (E) only at the neuroprotective IgG dose of 2.0 μg/ml (F) and not at 2000 μg/ml (G) (or in the absence of added IgG control), with measurements quantified as relative fluorescence intensity compared with control (H). [Respective relative levels were 1.68 ± 0.12 (n = 111 cells) and 1.00 ± 0.04 (n = 104) versus control (1.00 ± 0.04; n = 92)]. I–K, LAMP1 immunostaining, a specific marker for late endosomes or early lysosomes, showed a rise from control (I) after 2.0 μg/ml (J) that became significantly (p < 0.001; α = 1.00) greater than control at 200000 μg/ml IgG (with (K) relative levels of 1.13 ± 0.05 (n = 135) and 1.65 ± 0.14 (n = 124) vs control (1.00 ± 0.05; n = 105)). Scale bars, 10 μm. Data represent mean ± SEM and significance (*p < 0.05).
of reasons including changes in vesicle pH (Mukherjee et al., 1997) and related processing via lysosomes. This could quench bead fluorescence and so falsely indicate a drop in uptake. Thus, we proceeded to immunostaining to detect potential changes in specific endocytotic vesicle trafficking. We used immunostaining for RAB11a, specific for recycling endocytosis (Ang et al., 2004; Streit, 1995), to probe for changes in microglial recycling endocytosis from IgG, and found it to be significantly enhanced at 2.0 but not 2000 ng/ml. Immunostaining for LAMP1, specific for late endosomes/early lysosomes (Murray et al., 2005), showed no significant increase at 2.0 ng/ml but a significant increase at 2000 ng/ml. Although this is the normal path followed by immune complexes taken up by macrophages (Ukkonen et al., 1986), perhaps high dose monomeric IgG consistent with that seen with other high level ligand-receptor interactions (Pandey, 2005), promotes lysosome trafficking.

**TNF-α involvement in IgG mediated recycling endocytosis and neuroprotection**

Macrophage surface membrane cusp involved with phagocytosis are the sites from which vesicular membrane trafficking from the Golgi (Ang et al., 2004; Streit, 1995) carrying TNF-α release the cytokine to the external milieu (Murray et al., 2005). Furthermore, although most often associated with injury, evidence exists to indicate that TNF-α also can be neuroprotective. Thus, we tested whether microglia, a myeloid cell related to macrophages (Streit, 1995), might also release TNF-α in response to IgG (3 d exposure) and whether this release could account for the neuroprotection seen from IgG (Fig. 4). We found that IgG triggered significant increases in TNF-α expression in primary microglia and slice cultures that resembled U-shaped dose-response curves. For comparisons, maximal TNF-α levels were 891 ± 97 pg/ml for microglia (20 μg/ml IgG) and 1048 ± 98 pg/mg for slice cultures (20 μg/ml IgG), levels seen with noninjurious activation of brain tissue (Kunkler et al., 2004) and previously used by Wilde and coworkers (2000) in vitro with serum-free media to evoke neuroprotection in slice cultures. We speculate the significant drop in TNF-α at 0.2 μg/ml IgG (and to a lesser extent 2.0 μg/ml IgG) may be attributable to a concomitant greater increased expression of TNF receptor 1 or sTNFR1 by TNF-α (Oppenheim and Feldmann, 2001) at this dose. This follows from the fact that TNF-α stimulates expression of TNFR1 (both soluble and membrane bound forms) and the Kd for TNFR1 is 0.1–1.0 nM (Oppenheim and Feldmann, 2001).

Next, we confirmed that IgG-based neuroprotection requires TNF-α (Fig. 3). Three day treatment with 100 pg/ml TNF-α significantly reduced NMDA injury, thus mimicking neuroprotection from IgG. Heat inactivation of TNF-α removed the neuroprotective effect. Furthermore, treatment with previously neuroprotective IgG (20 μg/ml) that also contained 200 ng/ml sTNFR1 (to abrogate TNF-α signaling) removed neuroprotection.

IgG-mediated neuroprotection from OGD also requires TNF-α. Three day treatment with 100 pg/ml TNF-α significantly reduced injury from OGD (Fig. 4) and resembled the degree of protection seen from monomeric IgG. Treatment with previously neuroprotective 2.0 μg/ml IgG that also contained sTNFR1 (200 ng/ml) removed neuroprotection.

Microglia are the principal source of TNF-α in brain associated with irreversible injury such as that seen with ischemic brain injury (Gregersen et al., 2000). However, whether these cells are also the main source of TNF-α after noninjurious brain activation is uncertain. Cytokine mRNA is faithfully processed to related protein expression (Oppenheim and Feldmann, 2001). Accordingly, we used laser dissection microscopy coupled with real-time RT-PCR to determine whether microglia preferentially trigger brain production of TNF-α after spreading depression, a robust but noninjurious perturbation of brain (Nedergaard and Hansen, 1988; Kunkler et al., 2004) known to rapidly trigger increased production of TNF-α (Kunkler et al., 2004). We examined spreading depression because unlike long-term potentiation evoked from a stimulating electrode, spreading depression uniformly activates involved neural tissue. This lessens the likelihood for sampling errors resulting from harvesting cells from nonactivated brain. One hour of recurrent spreading depression triggered a preferential and significant elevation of TNF-α mRNA in microglia compared with astrocytes or neurons (Fig. 5). Because cytokines can be low expression species, we also simultaneously monitored interleukin-1 β to further establish that microglia can be the main source of so-called “effector” innate cytokines (Oppenheim et al., 2001) at this dose. This follow-up surpassed 0.10 (control 1.00 ± 0.04 (n = 14) and 0.98 ± 0.04 (n = 15) compared with control (1.00 ± 0.05; n = 18)). Data represent mean ± SEM and significance (*p < 0.05).
penheim and Feldmann, 2001) with non-injurious activation of brain (Fig. 5). Our results showed that interleukin-1 \( \beta \) mRNA also preferentially rose in microglia 1 h after 1 h of spreading depression.

**Minocycline prevents IgG-neuroprotection and microglial activation**

Minocycline increases neuronal survival when administered after the onset of excitotoxic injury (Tikka et al., 2001) and abrogates microglial activation (Tikka et al., 2001; Lai and Todd, 2006). Accordingly, we administered minocycline (10 \( \mu \)M) with IgG to slice cultures for 3 d and confirmed that it prevented IgG-induced neuroprotection against both NMDA and OGD (Fig. 6). With NMDA, pretreatment with 2.0 and 20 \( \mu \)g/ml IgG was neuroprotective (Fig. 1) but no significant protection occurred (over the range 0.2, 2.0, 20, 200, and 2000, \( \mu \)g/ml IgG) with inclusion of minocycline. Also, minocycline pretreatment alone had no impact on injury severity. Similarly, although 0.2, 2.0 and 20 \( \mu \)g/ml IgG alone were protective against OGD (Fig. 1), no significant neuroprotection was evident when minocycline was included. Minocycline alone had no impact on OGD injury severity.

Twenty minute minocycline (10 \( \mu \)M) exposure was also sufficient to prevent increased endocytosis as well as increased recycling endocytosis at IgG-neuroprotective doses (Fig. 7). At 0.2 \( \mu \)g/ml IgG, minocycline abrogated the previously seen significant increase in endocytosis (Fig. 3) and lowered endocytosis seen at 2.0 \( \mu \)g/ml to a significant decline. Minocycline had no impact on reductions in IgG-induced endocytosis (Fig. 3) seen at 20–2000 \( \mu \)g/ml IgG, which remained significantly lower than control. Also, minocycline changed the significant increase in recycling endocytosis that was previously seen (Fig. 3) at 2.0 \( \mu \)g/ml IgG to a significant decrease (Fig. 7). However, minocycline amplified recycling endocytosis at 2000 \( \mu \)g/ml from a nonsignificant relative level of 1.00 (Fig. 3) to a significant level of 3.17. Similarly, minocycline amplified the significant level of lysosomes seen at 2000 \( \mu \)g/ml IgG from 1.65 (Fig. 3) to 3.16 without a significant change at 2.0 \( \mu \)g/ml (Fig. 7).

Three day minocycline (10 \( \mu \)M) exposures also changed TNF-\( \alpha \)-release levels in response to IgG in both primary microglia and slice cultures (Fig. 7). Although IgG responses in primary microglia remained significantly greater than control and retained the U-shaped response, they were significantly less than that seen from IgG alone (Fig. 3) from 2.0–2000 \( \mu \)g/ml IgG. Minocycline had an even greater inhibition of TNF-\( \alpha \)-production from IgG in slice cultures (Fig. 7). Furthermore, whereas minocycline alone did not affect primary microglial production of TNF-\( \alpha \), it significantly inhibited TNF-\( \alpha \) production in slice cultures.

These results show that minocycline stopped microglial increased recycling endocytosis and abrogated neuroprotection from a physiological level of IgG (i.e., 0.2–20 \( \mu \)g/ml). Minocycline also prevented the related increased TNF-\( \alpha \) release in slice cultures at this neuroprotective dose. These findings further support the suggestion that physiologically activated microglia (i.e., to a primed state) protect neurons (Streit, 2002). Minocycline also amplified levels of recycling endocytosis and lysosomal vesicles at 2000 \( \mu \)g/ml without associated increased TNF-\( \alpha \) expression. Thus, endosomal vesicle trafficking can be dissociated from TNF-\( \alpha \) production/release in microglia by pharmacological maneuvers, high ligand [i.e., IgG (Fig. 3)] levels or their amplification via EP2-activation (see below).

**Prostaglandin enhances microglial recycling endocytosis**

Finally, because microglia affect neurons via IgG-induced recycling endocytosis and TNF-\( \alpha \), we asked whether neurons might affect these microglial processes. If so, monomeric IgG might reciprocally couple normal neuronal and microglial functions.

We focused to EP2-activation using Butaprost, an agonist for this receptor, as an exemplary paracrine signal of neuronal activity for several reasons. First, EP2-activation using Butaprost is neuroprotective (McCullough et al., 2004). Second, EP2 receptors are found on microglia (Caggiano and Kraig, 1999). Third,
Exposure to IgG and IgG plus EP2-activation triggered a significant increase in recycling endocytosis over that seen with IgG alone. Third, IgG alone triggered a nonsignificant increase in early lysosomes, which became significant when IgG was coincubated with EP2-activation, and returned to a nonsignificant elevation with EP2-activation. EP2-activation also amplified the IgG-induced TNF-α change in primary microglia (Fig. 8). Three day exposure to IgG and IgG plus EP2-activation triggered significantly increased expression of TNF-α, whereas EP2 activation alone had no effect. Coincubation with EP2-activation and IgG significantly increased TNF-α over that seen with IgG alone.

Finally, in light of the above results and because EP2-activation reduces excitotoxic injury (McCullough et al., 2004), we reasoned the EP2-activation neuroprotection might involve TNF-α. Thus, we removed the latter signaling via inclusion of sTNFR1 (Fig. 8) with EP2-activation. EP2-activation for 3 d triggered a significant reduction in injury from NMDA as expected, but co-incubation with sTNFR1 removed this protective effect, a level of injury that was comparable with controls and significantly greater than with EP2-activation alone.

Discussion

The present findings show that in the brain monomeric IgG is not simply a quiescent immuno protein poised to become active via immune complex formation associated with disease. Instead, monomeric IgG at physiological levels increases resilience of brain against excitotoxic injury in a U-shaped dose-response. This IgG-based neuroprotection involves similar U-shaped microglial activation responses that include increased recycling endocytosis and TNF-α production, two previously unrelated microglial functions that are amplified by EP2-activation.

Proinflammatory immune signaling is increasingly recognized as a concomitant of normal brain function. Major histocompatibility complex expression, which traditionally is known for its involvement in antigen presentation within the immune system, is upregulated during neural development and by activity-dependent synaptic plasticity (Huh et al., 2000; Bourlanger and Shatz, 2004). TNF-α, also recognized for its involvement in synaptic plasticity (see below), increases major histocompatibility complex expression (Neumann et al., 1997). Furthermore, reactive (to a primed state) microglia are involved in neurogenesis and spatial learning in adults (Ziv et al., 2006). Monomeric IgG can now be included in this same benign context.

Considerations of brain IgG signaling have previously focused on its role in cross-linking Fc receptors via immune complex reactions associated with disease. Such cross-linking activates low proinflammatory immune signaling is increasingly recognized as a concomitant of normal brain function. Major histocompatibility complex expression, which traditionally is known for its involvement in antigen presentation within the immune system, is upregulated during neural development and by activity-dependent synaptic plasticity (Huh et al., 2000; Bourlanger and Shatz, 2004). TNF-α, also recognized for its involvement in synaptic plasticity (see below), increases major histocompatibility complex expression (Neumann et al., 1997). Furthermore, reactive (to a primed state) microglia are involved in neurogenesis and spatial learning in adults (Ziv et al., 2006). Monomeric IgG can now be included in this same benign context.

Figure 6. Minocycline abrogated IgG-based neuroprotection from excitotoxic injury. A. Injury from NMDA: minocycline (mino) pretreatment (gray) significantly removed the neuroprotective effect of 2.0 and 20 μg/ml IgG (p < 0.002; α = 1.00) and had no impact on control on the severity of excitotoxic injury from NMDA when used alone. For comparison, respective injury levels without minocycline (white) from Figure 1 are shown. (Respective relative injury levels over the full dose range were (n = 23/group) 1.12 ± 0.10, 1.10 ± 0.10, 1.10 ± 0.06, 1.02 ± 0.06, 1.00 ± 0.06, and 1.01 ± 0.10 versus control (1.00 ± 0.03; n = 13)). B. Injury from OGD: minocycline (mino) pretreatment (gray) had no impact on injury severity from OGD and significantly removed the neuroprotective effects otherwise seen from 0.2, 2.0, and 20 μg/ml IgG (p < 0.001; α = 1.00). (Respective relative injury levels over the full dose range were (n = 15/group) 1.05 ± 0.04, 1.03 ± 0.04, 1.04 ± 0.07, 1.08 ± 0.07, 0.98 ± 0.06 and 1.09 ± 0.04 vs control (1.00 ± 0.03; n = 12/group)). Data represent mean ± SEM and significance (*p < 0.05).

PGE2, which activates EP2 receptors in vivo, is increased with neuronal activity (Yamagata et al., 1993). Fourth, PGE2 amplifies endocytosis in macrophages and so might have a similar effect on microglia (Wainszelbaum et al., 2006).

Three day exposure of primary microglia to IgG (20 μg/ml) with or without EP2-activation (using 10 nM Butaprost) was used to determine whether EP2-activation augmented effects seen with IgG alone (Fig. 8). Brief 20 min exposures [like that which could initiate increased endocytosis and recycling endocytosis from IgG (Fig. 3)] did not evoke an amplification of responses to EP2-activation. For example, relative fluorescence of nanosphere endocytosis for 2.0 μg/ml IgG+EP2-activation and EP2-activation were 1.20 ± 0.05 (n = 87) and 1.24 ± 0.08 (n = 92) whereas those for RAB11a immunostaining were 1.57 ± 0.04 (n = 84) and 1.61 ± 0.10 (n = 68) and with associated P values of 0.571 and 0.062, respectively. However, three day exposures triggered significant amplifications. First, the latter confirmed a significant increase in endocytosis for IgG and IgG plus EP2-activation but not EP2-activation alone. Furthermore, EP2-activation and IgG coinubcation significantly increased endocytosis over that seen with IgG alone. Second, three day exposures triggered a significant increase in recycling endocytosis for IgG and IgG plus EP2-activation but not EP2-activation alone.

Considerations of brain IgG signaling have previously focused on its role in cross-linking Fc receptors via immune complex reactions associated with disease. Such cross-linking activates low proinflammatory immune signaling is increasingly recognized as a concomitant of normal brain function. Major histocompatibility complex expression, which traditionally is known for its involvement in antigen presentation within the immune system, is upregulated during neural development and by activity-dependent synaptic plasticity (Huh et al., 2000; Bourlanger and Shatz, 2004). TNF-α, also recognized for its involvement in synaptic plasticity (see below), increases major histocompatibility complex expression (Neumann et al., 1997). Furthermore, reactive (to a primed state) microglia are involved in neurogenesis and spatial learning in adults (Ziv et al., 2006). Monomeric IgG can now be included in this same benign context.

Figure 6. Minocycline abrogated IgG-based neuroprotection from excitotoxic injury. A. Injury from NMDA: minocycline (mino) pretreatment (gray) significantly removed the neuroprotective effect of 2.0 and 20 μg/ml IgG (p < 0.002; α = 1.00) and had no impact on control on the severity of excitotoxic injury from NMDA when used alone. For comparison, respective injury levels without minocycline (white) from Figure 1 are shown. (Respective relative injury levels over the full dose range were (n = 23/group) 1.12 ± 0.10, 1.10 ± 0.10, 1.10 ± 0.06, 1.02 ± 0.06, 1.00 ± 0.06 and 1.01 ± 0.10 versus control (1.00 ± 0.03; n = 13)). B. Injury from OGD: minocycline (mino) pretreatment (gray) had no impact on injury severity from OGD and significantly removed the neuroprotective effects otherwise seen from 0.2, 2.0, and 20 μg/ml IgG (p < 0.001; α = 1.00). (Respective relative injury levels over the full dose range were (n = 15/group) 1.05 ± 0.04, 1.03 ± 0.04, 1.04 ± 0.07, 1.08 ± 0.07, 0.98 ± 0.06 and 1.09 ± 0.04 vs control (1.00 ± 0.03; n = 12/group)). Data represent mean ± SEM and significance (*p < 0.05).
cytosis associated with disease to the benign process of microglial recycling endocytosis related to monomeric IgG, which might function as a parsimonious link between neuronal activity and TNF-α release in normal brain.

Evidence also supports involvement of the innate cytokine, TNF-α, in normal brain function. Beattie and coworkers (2002) show that TNF-α, released from glia, enhances synaptic efficacy by increasing AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors in cultured neurons. Stellwagen and Malenka (2006) went on to show that glial TNF-α also drives increased expression of AMPA receptors as a synaptic scaling response to activity deprivation from tetrodotoxin. Importantly, such AMPA receptor expression increases are also seen after long-term potentiation, a well accepted cellular model of learning (Park et al., 2004). Furthermore, environmental enrichment, which results in increased hippocampal learning and is neuroprotective (Will et al., 2004), triggers increased expression of AMPA receptor expression (Naka et al., 2005), which involves increased expression of TNF-α. Thus, although TNF-α is not a requisite for long-term potentiation (Kaneko et al., 2008), it is involved in activity-dependent neuroprotection that results from long-term potentiation (Kraig et al., 2006) and spreading depression (Kraig et al., 2005) and it is also elevated by environmental enrichment (Kraig et al., 2003). Although TNF-α release conceivably can come from neurons or glia (Beattie et al., 2002; Stellwagen and Malenka, 2006), our studies focused to its release from microglia because these cells are the principal source of TNF-α in activated brain in vivo (Gregersen et al., 2000) after brain injury. In addition, monomeric IgG reacts specifically with this brain cell subtype under conditions unassociated with injury but whether microglia are the main source of TNF-α under such conditions is unknown. Accordingly, we showed that after noninjurious activation of brain from spreading depression (Nedergaard and Hansen, 1988; Kunkler et al., 2004, 2005) TNF-α also emanates from microglia. Attempts to confirm that long-term potentiation also triggered TNF-α production restricted to microglia have thus far been unsuccessful. We suspect this is caused by sampling difficulties associated with the small region activated by electrical stimulation. Nonetheless, this published literature and our results here begin to suggest that recycling endocytosis of IgG might be a means to coordinate changes in synaptic activity with TNF-α production from microglia.

To begin exploring a potential link between neuronal activity and microglial recycling endocytosis, TNF-α production plus related neuroprotection, we tested whether paracrine signaling proportionate to synaptic activity could amplify these IgG-mediated effects. We chose PGE₂ as an exemplary paracrine signal because its release to interstitial space is directly related to neuronal activity (Yamagata et al., 1993). PGE₂ acts via four E-prostanoid receptors, with the EP2 receptor isoform expressed on microglia (Caggiano and Kraig, 1999) and its activation via the selective agonist Butaprost is known to be neuroprotective (McCullough et al., 2004). EP2 receptors are also found on neurons, which was the focus of McCullough and coworkers (2004) who concluded that Butaprost’s neuroprotective effects were caused by this neural cell type. Although our results cannot exclude neuronal involvement, they extend considerations of EP2-activation to amplification of adaptive IgG-mediated microglial changes of recycling endocytosis and TNF-α production as well as related neuroprotection. Furthermore, the results indicate that microglial recycling endocytosis and related TNF-α production can be modulated by paracrine signals, which may include those from neuronal activity.
is tied to recycling endocytosis (and not lysosomal trafficking) because high dose IgG alone, which enhanced ED-1 (Fig. 2) and

Importantly, minocycline abrogated neuroprotection at physiological effects can be modulated by pharmacological manipulation (e.g., from monomeric IgG) before disease onset. Instead, signaling modifications downstream of receptor mediated endocytosis may be involved. For example, receptor mediated recycling endocytosis of transferrin receptors activates extracellular signal kinase 1/2 and p38 mitogen-activated protein kinase (Calzolari et al., 2006), pathways that might be similarly activated by microglial recycling endocytosis of IgG. Extracellular signal kinase 1/2 and p38 mitogen-activated protein kinase are involved TNF-α expression (Oppenheim and Feldmann, 2001) and minocycline inhibits p38 mitogen-activated kinase (Alano et al., 2006). IgG-receptor downstream signaling amplification involved in TNF-α expression from primary microglia may explain how small increases in low levels of added IgG produced significant but small increases in recycling endocytosis (Fig. 3G) and significant and large changes in TNF-α (Fig. 4A). In addition, minocycline inhibits TNF-α production from microglia without inhibiting phagocytosis of amyloid β (Familian et al., 2007). This is consistent with our data that shows minocycline can dissociate physiological IgG-mediated endocytosis and related TNF-α production (Fig. 7). Why minocycline alone did not affect primary microglial production of TNF-α but significantly inhibited TNF-α production from microglia in slice cultures is unclear. Such differential effects may stem from the impact of minocycline on other cell types, and learning from environmental enrichment (Ziv et al., 2006). Thus, our findings and this literature further support the notion that proinflammatory changes unassociated with disease involving microglial activation (Streit, 2002) can be nutritive (Hadley, 2003).

The mechanisms responsible for these minocycline effects are unknown. However, some insights can be gleaned from the published literature. Minocycline inhibits PARP-1 [poly(ADP-ribose) polymerase-1] which is activated by DNA damage (Alano et al., 2006). However, although this potential mechanism might play a role in reducing injury after the onset of disease, it is unclear how such inhibition would remove neuroprotection (e.g., from monomeric IgG) before disease onset. Indeed, signaling modifications downstream of receptor mediated endocytosis may be involved. For example, receptor mediated recycling endocytosis of transferrin receptors activates extracellular signal kinase 1/2 and p38 mitogen-activated protein kinase (Calzolari et al., 2006), pathways that might be similarly activated by microglial recycling endocytosis of IgG. Extracellular signal kinase 1/2 and p38 mitogen-activated protein kinase are involved TNF-α expression (Oppenheim and Feldmann, 2001) and minocycline inhibits p38 mitogen-activated kinase (Alano et al., 2006). IgG-receptor downstream signaling amplification involved in TNF-α expression from primary microglia may explain how small increases in low levels of added IgG produced significant but small increases in recycling endocytosis (Fig. 3G) and significant and large changes in TNF-α (Fig. 4A). In addition, minocycline inhibits TNF-α production from microglia without inhibiting phagocytosis of amyloid β (Familian et al., 2007). This is consistent with our data that shows minocycline can dissociate physiological IgG-mediated endocytosis and related TNF-α production (Fig. 7). Why minocycline alone did not affect primary microglial production of TNF-α but significantly inhibited TNF-α production from microglia in slice cultures is unclear. Such differential effects may stem from the impact of minocycline on other cell types, and learning from environmental enrichment (Ziv et al., 2006). Thus, our findings and this literature further support the notion that proinflammatory changes unassociated with disease involving microglial activation (Streit, 2002) can be nutritive (Hadley, 2003).

Minocycline provided additional evidence that IgG-mediated physiological effects can be modulated by pharmacological maneuvers. Minocycline is an anti-inflammatory agent and retards microglial inflammatory change and related injury after the onset of neurological disease (Tikka et al., 2001; Lai and Todd, 2006). Importantly, minocycline abrogated neuroprotection at physiological IgG doses and the related transformation of microglia to reactive species as evidenced by recycling endocytosis and related TNF-α production. Minocycline also prevents microglial activation in slice cultures that influence microglial function.

There is increasing new recognition of the concept that a toxin brought below threshold can become a nutrient. For example, this concept is a central tenet of ischemic preconditioning where stimuli associated with increased neural cell death after the onset of injury become nutritive when they are only "irritants" before the onset of disease (Dirnagl et al., 2003). Our data begin to indicate that intrinsic brain signaling (e.g., via IgG) can be a stimulus that functions in this same way. The U-shaped dose-
responses for IgG-mediated neuroprotection and microglial activation (i.e., increased recycling endocytosis and TNF-α production) follow a pattern termed hormesis or “… a dose–response relationship phenomenon characterized by low-dose stimulation and high dose inhibition” (Calabrese and Baldwin, 2003; Hadley, 2003). Interestingly, this same response pattern is also seen with drug treatments for stroke (Calabrese, 2008). High TNF-α concentrations increase ischemic injury when administered into brain a day before focal ischemia (Barone et al., 1997). Alternatively, like others (Wilde et al., 2000), we showed that low concentration TNF-α is neuroprotective and can be elevated by monomeric IgG, perhaps via neuronal activity, to low and nutritive levels. Together, our results begin to suggest unexpected mechanisms by which brain functions can converge to result in increased TNF-α production.

In summary, our studies show that monomeric IgG has signaling functions in uninjured brain involving adaptive, proinflammatory changes that, rather than accompanying injury, result in neuroprotection over time, which may be amplified by PGE₂. Microglial IgG-related recycling endocytosis and associated production of TNF-α are previously unrecognized targets for deciphering the bases of activity-dependent neuroprotection.

References
Hadley C (2003) What doesn’t kill you will make you stronger. A new model for risk assessment may not only revolutionize the field of toxicology, but also have vast implications for risk assessment. EMBO Rep 4:924–926.